C&G Editor in Chief, Erin Harris

  1. Inside Kyverna's Autoimmune CAR T Platform Beyond SPS 9/16/2026

    Kyverna's progress suggests that autoimmune CAR T's commercial viability will depend as much on manufacturing readiness and focused indication selection as on its potential to deliver durable, drug-free remission.

  2. Autoimmune CAR T Has Hit A Critical Moment. Are We Asking The Right Questions? 9/2/2026

    The promise of autoimmune CAR T is enormous, but recent safety pauses from Novartis and BMS underscore why the field needs a more patient-centered approach to risk, clinical outcomes, access, and real-world delivery.

  3. Why Celcuity's REVTORPYK Creates A New Path For Precision Oncology 8/28/2026

    REVTORPYK's FDA approval highlights the broader push toward precision therapies that address complex disease biology, overcome resistance, and deliver more durable patient benefit.

  4. In Vivo CAR T Needs More Than Better Cell Engineering 8/26/2026

    In vivo CAR T’s potential to expand access and simplify manufacturing hinges on targeted LNP delivery and solving the durability challenge.

  5. Reimagining Solid Tumor Immunotherapy With SRC-3-Edited Tregs 8/20/2026

    CoRegen’s investigational autologous cell therapy, CRG-150, is designed to disrupt tumor-driven immune suppression by knocking out SRC-3 in Tregs, potentially exposing solid tumors to the patient’s own immune response without lymphodepletion.

  6. Building Antigen-Specific Immune Tolerance For Autoimmune Disease 8/10/2026

    Antigen-specific immune tolerance could redefine autoimmune disease treatment by precisely retraining the immune system rather than broadly suppressing it.

  7. Solving Vector Yield Challenges Starts Long Before Manufacturing 7/22/2026

    Cell & Gene Live panelists take a deep dive into why solving vector yield challenges begins with early biological and manufacturing decisions rather than process optimization alone.

  8. Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors 7/17/2026

    US WorldMeds' expanded FDA approval for TECELRA represents another important step forward for engineered cell therapies in solid tumors.

  9. FDA Approval Of TREGZI Signals A New Era For Precision Engineered Cell Therapy 7/9/2026

    Following the FDA approval of TREGZI, Orca Bio's precision engineered allogeneic cell therapy is redefining stem cell transplantation through improved immune control, advanced manufacturing, and a platform designed to expand the future of cell therapy.

  10. How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale 6/29/2026

    Our latest Cell & Gene Live examined how CGT developers can choose manufacturing models that support long-term commercial success by aligning biology, operations, supply chain, and scalability from the earliest stages of development.